Compare Neurocrine Biosciences Inc (NBIX) vs PayPal Holdings, Inc. (PYPL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Neurocrine Biosciences Inc vs PayPal Holdings, Inc. — how do they compare? Neurocrine Biosciences Inc trades at $142.88 (market cap $14.36B), while PayPal Holdings, Inc. trades at $55.39 (market cap $47.07B). The key difference: PayPal Holdings, Inc. is far larger — about 3.3× Neurocrine Biosciences Inc's market cap, and PayPal Holdings, Inc. pays a 1.02% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Neurocrine Biosciences Inc for 23 Days and PayPal Holdings, Inc. for 106 Days on average.
| NBIX | PYPL | |
|---|---|---|
Market Cap | $14.36B | $47.07B |
Volume | 1,237,180 | 13,860,099 |
Sector | Health | Financials |
52-Week High | $185.50 | $75.75 |
52-Week Low | $123.10 | $39.08 |
Typical Hold Time | 23 Days | 106 Days |
Enterprise Value | $14.37B | $49.21B |
Dividend Yield | — | 1.02% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Neurocrine Biosciences (NBIX) trades at $141.69, down 1.24% on the day, with a bearish technical signal from moving averages. Fundamentally, the company shows strong profitability with a 20.91% net income margin and consistent earnings beats, including a significant Q2 2026 beat. Recent news highlights pipeline advancements and executive appointments, while analyst sentiment remains overwhelmingly positive.
The outlook for NBIX is supported by robust fundamentals and strong analyst buy ratings, but near-term price action is challenged by technical bearishness. Key opportunities include product diversification and pipeline growth, while risks involve execution of expansion plans and potential pricing pressures on key products like INGREZZA.
PayPal (PYPL) trades at $55.47, up 0.95% today, with a bullish technical outlook supported by moving averages. The stock shows strong fundamentals with a P/E of 10.4, net income margin of 14.36%, and consistent revenue growth from $33.17B in 2025 to $34.1B projected for 2026. Recent positive developments include a Meta partnership for AI-powered checkout and three consecutive quarterly earnings beats.
PYPL presents a compelling value opportunity with attractive valuation multiples and solid profitability, though investors face risks from checkout competition and slowing growth. Analyst consensus leans cautious with 60% hold ratings, but the $56.41 price target suggests modest upside potential from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →About PayPal Holdings, Inc.
PayPal Holdings, Inc. operates as a technology platform company that enables digital and mobile payments on behalf of consumers and merchants. The Company offers online payment solutions. PayPal Holdings serves customers worldwide.
Read more on PYPL →
